Status:

COMPLETED

Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients

Lead Sponsor:

Qlaris Bio, Inc.

Conditions:

Primary Open Angle Glaucoma (POAG)

Primary Open Angle Glaucoma of Both Eyes

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in primary open-angle glaucoma (POAG) or ocular hypertension patients.

Detailed Description

A randomized, active- and vehicle-controlled, multi-site, double-masked study to evaluate the safety and tolerability of QLS-111 versus vehicle in subjects with primary open-angle glaucoma or ocular h...

Eligibility Criteria

Inclusion

  • 18 years or older
  • Able to provide written acknowledgement of giving informed consent
  • Best corrected visual acuity (BCVA) 20/200 or better Bilateral POAG or OHT with documented historic IOP value(s) ≥24 mmHg, in either eye
  • Post-washout IOP ≥22 mmHg in morning on Visits 2 and 3 and ≥18 mmHg at noon on Visit 2

Exclusion

  • IOP \>34 mmHg
  • Severe glaucomatous damage that would preclude safe washout of prescribed ocular hypotensive medications
  • Previous glaucoma surgery, certain procedures (trabeculotomy, shunt/tubes, cyclodestructive procedure) (selective laser trabeculoplasty (SLT) allowed if done no earlier than 1 year from study, some minimally invasive glaucoma surgeries are allowed if done no earlier than 1 year from study)
  • Ocular trauma, ocular infections, ocular inflammation, herpes simplex keratitis of eye
  • Use of other ophthalmic concomitant medications during the study
  • Uncontrolled hypertension or hypotension
  • Significant systemic or psychiatric disease
  • Participation in other investigational trial 30 days prior to screening or previous enrollment and treatment with Qlaris investigational product
  • Pregnant or lactating

Key Trial Info

Start Date :

March 5 2024

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 20 2024

Estimated Enrollment :

63 Patients enrolled

Trial Details

Trial ID

NCT06016972

Start Date

March 5 2024

End Date

August 20 2024

Last Update

January 20 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Coastal Research Associates, LLC

Roswell, Georgia, United States, 30076

Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients | DecenTrialz